Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib

  • Kobialka, Piotr|||0000-0003-4765-168X
  • Sabata Perez, Helena|||0000-0003-0637-0638
  • Vilalta, Odena
  • Gouveia, Leonor|||0000-0002-3825-8571
  • Angulo-Urarte, Ana|||0000-0002-8024-814X
  • Muixí, Laia
  • Zanoncello, Jasmina
  • Muñoz-Aznar, Oscar
  • Olaciregui, Nagore G.
  • Fanlo-Escudero, Lucía|||0000-0002-8364-9520
  • Esteve-Codina, Anna|||0000-0003-0361-2873
  • Lavarino, Cinzia
  • Javierre, B. M.|||0000-0002-8682-6748
  • Celis, Verónica Paola
  • Rovira, Cinzia
  • López-Fernández, Susana
  • Baselga Torres, Eulàlia|||0000-0003-1086-8439
  • Mora, J.
  • Castillo, Sandra D.|||0000-0002-7007-3155
  • Graupera, Mariona|||0000-0003-4608-4185
Low-flow vascular malformations are congenital overgrowths composed of abnormal blood vessels potentially causing pain, bleeding and obstruction of different organs. These diseases are caused by oncogenic mutations in the endothelium, which result in overactivation of the PI3K/AKT pathway. Lack of robust in vivo preclinical data has prevented the development and translation into clinical trials of specific molecular therapies for these diseases. Here, we demonstrate that the Pik3ca activating mutation in endothelial cells triggers a transcriptome rewiring that leads to enhanced cell proliferation. We describe a new reproducible preclinical in vivo model of PI3K-driven vascular malformations using the postnatal mouse retina. We show that active angiogenesis is required for the pathogenesis of vascular malformations caused by activating Pik3ca mutations. Using this model, we demonstrate that the AKT inhibitor miransertib both prevents and induces the regression of PI3K-driven vascular malformations. We confirmed the efficacy of miransertib in isolated human endothelial cells with genotypes spanning most of human low-flow vascular malformations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

New genetic drivers in hemorrhagic hereditary telangiectasia

  • Cerdà, Pau|||0000-0003-4368-6260
  • Castillo, Sandra D.|||0000-0002-7007-3155
  • Aguilera, Cinthia|||0000-0002-0363-8590
  • Iriarte, Adriana
  • Rocamora, José Luis
  • Larrinaga, Ane M.
  • Viñals, Francesc|||0000-0002-9918-6751
  • Graupera, Mariona|||0000-0003-4608-4185
  • Riera Mestre, Antoni|||0000-0001-9411-804X
Background: Hereditary hemorrhagic telangiectasia (HHT) is a rare vascular disease inherited in an autosomal dominant manner. Disease-causing variants in endoglin (ENG) and activin A receptor type II-like 1 (ACVRL1) genes are detected in around 90% of the patients; also 2% of patients harbor pathogenic variants at SMAD4 and GDF2. Importantly, the genetic cause of 8% of patients with clinical HHT remains unknown. Here, we present new putative genetic drivers of HHT. Methods: To identify new HHT genetic drivers, we performed exome sequencing of 19 HHT patients and relatives with unknown HHT genetic etiology. We applied a multistep filtration strategy to catalog deleterious variants and prioritize gene candidates based on their known relevance in endothelial cell biology. Additionally, we performed in vitro validation of one of the identified variants. Results: We identified variants in the INHA, HIF1A, JAK2, DNM2, POSTN, ANGPTL4, FOXO1 and SMAD6 genes as putative drivers in HHT. We have identified the SMAD6 p.(Glu407Lys) variant in one of the families; this is a loss-of-function variant leading to the activation of the BMP/TGFβ signaling in endothelial cells. Conclusions: Variants in these genes should be considered for genetic testing in patients with HHT phenotype and negative for ACVRL1/ENG mutations.